WO2018170710A1 - Vecteur d'expression élevée du gène imd16 humain et son application - Google Patents
Vecteur d'expression élevée du gène imd16 humain et son application Download PDFInfo
- Publication number
- WO2018170710A1 WO2018170710A1 PCT/CN2017/077397 CN2017077397W WO2018170710A1 WO 2018170710 A1 WO2018170710 A1 WO 2018170710A1 CN 2017077397 W CN2017077397 W CN 2017077397W WO 2018170710 A1 WO2018170710 A1 WO 2018170710A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- imd16
- pegfp
- expression vector
- gene
- pcr
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 17
- 239000013604 expression vector Substances 0.000 title claims abstract description 13
- 208000014136 immunodeficiency 16 Diseases 0.000 claims abstract description 50
- 239000013598 vector Substances 0.000 claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims abstract description 10
- 230000002018 overexpression Effects 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 6
- 238000010276 construction Methods 0.000 claims abstract description 4
- 239000002299 complementary DNA Substances 0.000 claims description 9
- 102000012410 DNA Ligases Human genes 0.000 claims description 6
- 108010061982 DNA Ligases Proteins 0.000 claims description 6
- 238000000246 agarose gel electrophoresis Methods 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 238000012408 PCR amplification Methods 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 claims description 3
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 claims description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 239000012634 fragment Substances 0.000 claims description 3
- 229930027917 kanamycin Natural products 0.000 claims description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims description 3
- 229960000318 kanamycin Drugs 0.000 claims description 3
- 229930182823 kanamycin A Natural products 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 108091008146 restriction endonucleases Proteins 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 238000012215 gene cloning Methods 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims 1
- 238000010367 cloning Methods 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 16
- 239000013612 plasmid Substances 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 101150076401 16 gene Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 2
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000003208 gene overexpression Methods 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
Definitions
- the present invention belongs to the field of biotechnology, and relates to a method for constructing a human IMD16 gene high expression vector and an application thereof.
- IMD16 is a member of the TNF receptor superfamily and is a type I transmembrane glycoprotein.
- the expression profile of IMD16 is restricted to the surface of activated CD4+ and CD8+ T cells, and is CD4+
- IMD16L/CD 134L Human IMD16 ligand contained 183 amino acids in 1991 (extracellular 139 amino acids, transmembrane 21 amino acids, intracellular 23 amino acids), belonging to the TNF family, and is a scorpion-type transmembrane glycoprotein.
- IMD16/GP34 is an important co-stimulatory molecule that plays an important role in the body's immune response and various diseases. Its interaction can promote the activation, proliferation, migration, prolongation of life and promote hair growth of CD+4 T cells. The formation of the center and the differentiation and maturation of DC.
- the object of the present invention is to overcome the deficiencies in the prior art and to provide a method for constructing a human IMD16 gene expression vector.
- the overexpression vector pEGFP-Cl/IMD16 was constructed to lay a foundation for the subsequent study of human IMD16 gene function.
- a method for constructing a human IMD16 gene overexpression vector comprising the steps of:
- the purified PCR product and the eukaryotic expression vector pEGFP-Cl were digested with restriction enzymes Xho I and EcoR I, identified and recovered by 1% agarose gel electrophoresis;
- the target gene fragment was ligated with the same double-digested expression vector pEGFP-Cl; the reaction system was: 10XT4 DNA ligase Buffer 1 ⁇ , linearized pEGFP-Cl vector 1 ⁇ , PCR product 3 ⁇ , T4 DNA ligase 1 ⁇ , dH20 4 L, 4 °C ligation overnight; the ligation product was transformed into E.
- coli DH5ot competent cells ice bath for 30 min, heat shock at 42 °C for 90 s, immediately transferred to ice for 2 min, then added to 500 37
- the pre-warmed non-resistant LB medium was incubated at 37 °C for 1 h.
- the bacterial solution was uniformly coated on LB solid medium containing kanamycin, and placed in a 37 ° C incubator for overnight culture. Positive colonies were screened; 3 monoclonal colonies were randomly picked. After the colony PCR was positive, the bacterial liquid was sent to Shanghai Biotech for sequencing.
- the obtained recombinant eukaryotic expression plasmid was named pEGFP-Cl/IMD16.
- the present invention constructs the overexpression vector pEGFP-Cl/IMD16 of the IMD16 gene. Subsequent development of overexpression I MD16 gene will play an important role in IMD16-related drug research and development.
- Jurkat cells and 293T cells were purchased from ATCC, Premix PrimeSTAR
- HS enzyme was purchased from Takara, RNeasy Mini Kit was purchased from QIAGEN, Endo-Free Plasmid
- Mini Kit II was purchased from Omega bio-tek.
- Example 1 Cloning of the IMD16 gene [0016] Total RNA of Jurkat cells was extracted, reverse-transcribed into cDNA, primers (IMD16-F, IMD16-R) were designed, cDNA was used as a template, and primers and PrimeStar high-fidelity DNA polymerase were used for PCR amplification according to a conventional method. The reaction conditions were: 98 ° C 2 min; 98. C 10 s, 58. C 10 s, 72 ° C 50 s, 30 cycles; 72 ° C 5 min. The PCR amplification products were identified by agarose gel electrophoresis. The nucleotide sequence of IMD16-F is shown in SEQ ID No: 1, and the nucleotide sequence of IMD16-R is shown in SEQ ID No: 2.
- the purified PCR product and the eukaryotic expression vector pEGFP-Cl were digested with restriction enzymes Xho I and EcoR I, identified and recovered by 1% agarose gel electrophoresis;
- the target gene fragment was ligated with the same double-digested expression vector pEGFP-Cl; the reaction system was: 10XT4 DNA ligase Buffer 1 ⁇ , linearized pEGFP-Cl vector 1 ⁇ , PCR product 3 ⁇ , T4 DNA ligase 1 ⁇ , dH20 4 L, 4 °C ligation overnight; the ligation product was transformed into E.
- coli DH5ot competent cells ice bath for 30 min, heat shock at 42 °C for 90 s, immediately transferred to ice for 2 min, then added to 500 37
- the pre-warmed non-resistant LB medium was incubated at 37 °C for 1 h.
- the bacterial solution was uniformly coated on LB solid medium containing kanamycin, and placed in a 37 ° C incubator for overnight culture. Positive colonies were screened; 3 monoclonal colonies were randomly picked. After the colony PCR was positive, the bacterial liquid was sent to Shanghai Biotech for sequencing.
- the obtained recombinant eukaryotic expression plasmid was named pEGFP-Cl/IMD16.
- Escherichia coli containing the PEGFP-C1/IMD16 plasmid was cultured in large amounts, and the pEGFP-Cl/IMD16 plasmid was extracted from Endo-Free Plasmid Mini Kit II. 293T cells with good growth were inoculated into six wells with 1000 000 cells per well. After 18 h of culture, Lipofectamine was used.
- the pEGFP-Cl/IMD16 plasmid was transduced into 293T cells in 2000 and cultured for 48 h.
- the primer design software Oligo 7.0 was used to design the bow.
- the RT reagent kit reverse-transcribes mRNA into cDNA and stores it at -20 °C.
- Kit detected the relative expression of IMD16 gene in each group, and the results are shown in Figure 1. It can be seen that the expression level of IMD 16 gene in 293T cells transfected with pEG FP-C1/IMD 16 plasmid is more than 160-fold higher than that of normal 293T cells, indicating that the present invention provides PEGFP-C1/IMD16 plasmid specificity, Continuous, efficient, and stable promotion of high expression of IMD16 gene.
- the present invention constructs the overexpression vector pEGFP-Cl/IMD16 of the IMD16 gene. Subsequent development of overexpression I MD16 gene will play an important role in IMD16-related drug research and development.
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
L'invention concerne un procédé de construction d'un vecteur d'expression du gène IMD16 humain, qui comprend les étapes consistant à : (1) cloner un gène IMD16 ; et (2) construire un vecteur de surexpression pEGFP-C1/IMD16.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/077397 WO2018170710A1 (fr) | 2017-03-20 | 2017-03-20 | Vecteur d'expression élevée du gène imd16 humain et son application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2017/077397 WO2018170710A1 (fr) | 2017-03-20 | 2017-03-20 | Vecteur d'expression élevée du gène imd16 humain et son application |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2018170710A1 true WO2018170710A1 (fr) | 2018-09-27 |
Family
ID=63583897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2017/077397 WO2018170710A1 (fr) | 2017-03-20 | 2017-03-20 | Vecteur d'expression élevée du gène imd16 humain et son application |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2018170710A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2718868A1 (fr) * | 2008-03-18 | 2009-09-24 | Centre National De La Recherche Scientifique | Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes |
CN102061310A (zh) * | 2010-11-24 | 2011-05-18 | 中国人民解放军第四军医大学 | 人fhl1c真核表达载体的构建及其应用 |
CN102337297A (zh) * | 2011-10-21 | 2012-02-01 | 南京医科大学 | 一种mbr-FPGS高效表达载体及其构建方法和应用 |
-
2017
- 2017-03-20 WO PCT/CN2017/077397 patent/WO2018170710A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2718868A1 (fr) * | 2008-03-18 | 2009-09-24 | Centre National De La Recherche Scientifique | Polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leur utilisation pour la production de compositions immunogenes |
CN102061310A (zh) * | 2010-11-24 | 2011-05-18 | 中国人民解放军第四军医大学 | 人fhl1c真核表达载体的构建及其应用 |
CN102337297A (zh) * | 2011-10-21 | 2012-02-01 | 南京医科大学 | 一种mbr-FPGS高效表达载体及其构建方法和应用 |
Non-Patent Citations (1)
Title |
---|
LIU, HONGXIANG ET AL.,: "Advances in Research on TNF-TNFR Superfamily T Cell Costimulatory Molecules and Organ Transplantation", SURGERY FOREIGN MEDICAL SCIENCES, vol. 32, no. 6, 30 November 2005 (2005-11-30), pages 401 - 404 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109266650A (zh) | 一种诱导型启动子、其重组载体、转化体以及诱导基因表达的方法及其应用 | |
WO2018170710A1 (fr) | Vecteur d'expression élevée du gène imd16 humain et son application | |
WO2018170711A1 (fr) | Vecteur d'expression élevée du gène gp34 humain et son application | |
CN103031285B (zh) | 冬虫夏草中国被毛孢尿苷-胞苷激酶、编码基因及其应用 | |
WO2018170708A1 (fr) | Méthode de construction d'un vecteur d'expression du gène ila humain et son application | |
WO2018170709A1 (fr) | Vecteur d'expression du gène tnlg5a humain et son application | |
CN115838713A (zh) | 一种蛋白酶及其在l-肌肽合成中的应用 | |
WO2017214940A1 (fr) | Vecteur d'expression lentiviral pour favoriser spécifiquement l'expression élevée du gène cplx2, et ses applications | |
WO2019237391A1 (fr) | Inactivation ciblée par crispr/cas9 du gène txgp1 humain et arng spécifique associé | |
WO2019000145A1 (fr) | Procédé de construction de cellule cho recombinée exprimant fortement l'ampar | |
WO2019037133A1 (fr) | Arnsh ciblant app silencieux | |
WO2019000150A1 (fr) | Procédé de construction de cellule cho recombinée exprimant fortement le tl6 | |
CN103031286B (zh) | 冬虫夏草中国被毛孢尿苷酸-胞苷酸激酶、编码基因及应用 | |
WO2019000152A1 (fr) | Cellule cho exprimant le gène rhbdd1 et son utilisation | |
WO2019037053A1 (fr) | Arn court en épingle à cheveux du gène aitr humain et applications correspondantes | |
WO2019000144A1 (fr) | Cellule cho exprimant le gène aitr et utilisation associée | |
WO2018170764A1 (fr) | Vecteur pour arni et son application | |
WO2018170765A1 (fr) | Vecteur d'interférence arn du gène imd16 et son application | |
CN106591311B (zh) | 核酸及其用途 | |
WO2018170762A1 (fr) | Vecteur d'expression d'arni du gène tnlg5a, procédé de construction associé et application correspondante | |
WO2019036870A1 (fr) | Procédé de construction d'un vecteur d'expression élevée d'un gène arntl humain, et applications | |
WO2017214937A1 (fr) | Vecteur d'expression lentiviral pour favoriser l'expression du gène app, et ses applications | |
WO2019037054A1 (fr) | Procédé de construction de vecteur à expression élevée du gène cvid1 humain et applications | |
WO2017214938A1 (fr) | Vecteur d'expression lentiviral pour favoriser spécifiquement l'expression élevée du gène bace1, et ses applications | |
WO2019036869A1 (fr) | Arnsh du gène tl6 humain et ses applications |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17901841 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 17901841 Country of ref document: EP Kind code of ref document: A1 |